NXT629 (NXT-629) is a novel, potent, selective and competitive hPPAR-α antagonist (IC50 =77 nM) that may be beneficial in diseases such as ovarian cancer
and melanoma where PPARα and fatty acid oxidation are involved. Peroxisome-proliferator activated receptors (PPAR) are members of the
nuclear hormone receptor superfamily which regulate gene transcription.
PPARα is a key regulator of lipid homeostasis and a negative regulator
of inflammation. PPARα expression is upregulated in diseased tissues such as melanoma,
chronic lymphocytic leukemia, ovarian and prostate cancer.